in the absence of a submission from the holder of the marketing authorisation:
bezlotoxumab (Zinplava®) is not recommended for use within NHS Scotland.
Indication under review: Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
|Drug Name:||bezlotoxumab (Zinplava)|
|SMC Drug ID:||1293/17|
|Indication:||Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.|
|Submission Type:||Non submission|
|Date Advice Published:||11 December 2017|
To read more Press Release articles, click here.